1670P: Circulating tumor DNA dynamics of response and resistance in BRAF V600E mutant metastatic colorectal (mCRC) and other cancers: data from EVICT (Erlotinib and Vemurafenib In Combination Trial)

L. Tan1,2, B. Tran1,2, J. Tie1,2,3, E. Link1,2,4, S. Wong1,2, S. Chandrashekar1, J. Guinto1, B. Markman5, S. Ananda1, N.C. Tebbutt6, M. Michael1,2, B.J. Solomon1,2, G.A. McArthur1,2, P. Gibbs3, S-J. Dawson1,2,7, and J. Desai1,2

1Peter MacCallum Cancer Centre, Australia, 2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia, 3Division of Personalized Oncology, Walter and Eliza Hall Institute of Medical Research, Australia, 4Centre for Biostatistics and Clinical Trials, 5Monash Health, Australia, 6Olivia Newton John Cancer Wellness and Research Centre, Australia, 7Centre for Cancer Research, The University of Melbourne, Australia.

Introduction

- In the phase Ib/II EVICT trial, the combination of vemurafenib and erlotinib demonstrated promising efficacy with response rates of 32% (10/31; 85%: 5/31 confirmed) in patients (pts) with BRAF V600E mCRC and 43% (3/7) in pts with other cancers.
- The overall clinical benefit rate (partial response + stable disease) was 71% (27/38).
- Here we report the utility of circulating tumor DNA (ctDNA) as a biomarker to predict outcomes and understand mechanisms of treatment resistance.

Methods

- Serial plasma samples were available from 25 pts.
- Paired baseline and progression samples were analyzed by targeted sequencing (AVENIO ctDNA expanded assay, Roche diagnostics).
- Droplet digital PCR was used to serially monitor mutations of interest.

Summary

EVICT demonstrates that the combination of vemurafenib and erlotinib is well tolerated, with promising activity in BRAF V600E mCRC and other tumor types. Our findings highlight that ctDNA analysis can reveal important insights into mechanisms of treatment resistance and provides an early biomarker of treatment response.

Results

Baseline ctDNA analysis

- BRAF V600E mt ctDNA was detected at baseline in 21/25 pts (84%).
- Other frequently altered genes included TP53 (60%), EGFR (52%), and MET (40%).
- Mutational burden was higher in pts who did not derive a clinical benefit (P=0.04).
- MET amplification was associated with inferior overall survival (OS) (median 4.9 vs 8.8 months; HR 2.2; 95% CI 0.8-6.0, P=0.04).

ctDNA dynamics

- Decline in ctDNA levels between baseline and week 2 was greater in pts who derived clinical benefit (P<0.001).
- Decline in ctDNA variant allele fraction at 2 weeks predicted longer PFS (median 1.8 vs 6.4 months, HR 3.6, 95% CI 1.3-9.8, P<0.001) and OS (median 5.6 vs 9.9 months, HR 2.9, 95% CI 1.0-8.4, P<0.01).

Genomic evolution following treatment

- Of the 18 pts with available plasma at progression, 9/18 (50%) showed emergence of ≥ 1 KRAS or NRAS mutation.
- Polyclonal KRAS mutations were observed in 6/9 pts (67%).
- Other frequently acquired MAPK pathway alterations included MAP2K1 mutations (22%) and MET amplification (17%).

Conclusion

In pts with BRAF V600E mt cancers treated with vemurafenib and erlotinib, baseline ctDNA profile and an early decline in ctDNA were predictive of clinical outcomes. ctDNA analyses provided a mechanistic understanding of intrinsic and acquired resistance, revealing frequent evidence of convergent evolution and MAPK pathway reactivation as the dominant mechanism of therapeutic escape.

Figure 1. Landscape of somatic mutations detected through targeted sequencing of baseline plasma DNA in 25 pts enrolled on the EVICT trial.

Figure 2. Dynamics of BRAF V600E mutant DNA copies/mL between baseline, week 2 and week 4 of treatment according to clinical benefit.

Figure 3. Summary of ctDNA genomic features at disease progression in 18 pts.

Correspondence: jayesh.desai@petermac.org & sarah-jane.dawson@petermac.org

Disclosures: No conflicts of interest